Why Amylin Is Emerging as the Next Big Target in Weight Loss Drugs
Amylin analogues are emerging as the next major target in obesity therapeutics. BioSpace reported that as Novo Nordisk’s amylin and GLP-1 combination drug CagriSema nears a potential U.S. Food and ... Read More